RIVastigmine In Vascular cognitivE Impairment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that patients receiving Rivastigmine would improve in executive functioning domains.
Epistemonikos ID: c819334e398fb76f6b489ccb4df94c523341abd1
First added on: May 05, 2024